With new data expected this month from the Lillys SURMOUNT-2 trial, analysts are predicting up to $52B in peak sales of tirzepatide (for T2D, obesity, and other indications)
[2] [3] The GIP component appears to complement GLP-1 activity by reducing food intake, while also potentially improving insulin sensitivity in peripheral tissues
In parallel, there is growing focus on small molecule GLP-1R agonists , which have the potential to be administered orally, produced more cost-effectively, and offer improved stability and pharmacokinetic profiles
GLP-2 is a 33-amino-acid proglucagon-derived peptide, which is expressed in the small intestine, mainly in terminal ileum
The problem is scale
Proper peptide storage is critical for maintaining compound integrity